Christopher A. Guerreiro practises dispute resolution and litigation, with an emphasis on high-stakes cases involving intellectual property, administrative law, and other issues affecting the life sciences and high-technology industries.

Chris has spent much of his career working with innovators. As a litigator and advisor, he focusses on developing dispute-resolution strategies that align with the unique interests and business objectives of clients in this space—whether through litigation or a negotiated outcome.

He has particular experience acting in complex patent infringement, impeachment, and damages disputes before Canada's federal courts. Among them, he was counsel on the first series of patent infringement actions brought under section 6 of the new Patented Medicines (Notice of Compliance) Regulations. In addition to small-molecule and biologic drug cases, his patent litigation and related work has also involved a range of other technologies such as medical devices, vaccines, gene therapy, energy, consumer technology, and software.

Chris is regularly consulted on issues relating to the Patented Medicine Prices Review Board (PMPRB), and has acted as counsel in industry-wide administrative law challenges to regulations and guidelines governing the PMPRB. More broadly, he also advises on other matters that are susceptible to litigation under the Patent Act and related legislation.

Chris enjoys teaching as much as learning. He has lectured and led experiential learning sessions for Osgoode Hall Law School's representative negotiation course, "Lawyer as Negotiator." He has also volunteered as a judge for the Harold G. Fox Intellectual Property Moot, served as a "witness" for practising lawyers in Osgoode's "Intensive Trial Advocacy Workshop," and delivered lectures on a range of topics relating to intellectual property for graduate and law students.

Chris has been a member of the firm since joining as a summer student in 2011, and is proud to invest in the next generation of talent as a mentor and articling principal. He contributes to a number of programmes related to student and associate development, substantive legal knowledge, and team-building within the firm. He is also an active contributor to process development and technology adoption initiatives that drive efficiency in the delivery of legal services on complex mandates. Chris is an editor of our  Pharma in Brief bulletin and a frequent contributor to other firm publications.